Tryp Therapeutics Inc.

Tryp Therapeutics Appoints Dennis Langer, M.D., J.D. as Senior Advisor

San Diego, California – August 18, 2021 - Tryp Therapeutics (CSE:TRYP; OTCQB:TRYPF) (“Tryp” or the “Company”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the appointment of Dennis Langer, M.D., J.D., as Senior Advisor to the Company.

Dr. Langer has been a Director, Co-Founder, and CEO of various public and private biotechnology, specialty pharmaceutical, and diagnostic companies.  He previously served as Senior Vice President of Research and Development at GlaxoSmithKline and as CEO of Neose Technologies.  He currently serves as a Director of Myriad Genetics, Inc. (NASDAQ:MYGN) and the Whitehead Institute for Biomedical Research.  Dr. Langer previously served as a Director at several biotechnology companies that were successfully acquired including Pharmacopeia, Cytogen, Sirna Therapeutics, and Transkaryotic Therapies.  Dr. Langer earned a B.A. from Columbia University, an M.D. from the Georgetown University School of Medicine, and a J.D. (cum laude) from Harvard Law School.

Dr. Langer will be advising the Company on strategic matters related to Tryp's drug development programs for chronic pain and eating disorders as well as providing additional insights into the large pharma and investor communities.

“I am looking forward to advising Tryp Therapeutics as they near the initiation of Phase 2a clinical trials this year,” said Dr. Langer. “The Company continues to execute on its milestones and is unique in their strategy to deliver psilocybin-based solutions to chronic pain and other indications with critically unmet needs.  The ultimate commercial potential for Tryp’s products is significant.”

Commenting on the appointment, Greg McKee, Chairman and Chief Executive Officer of Tryp Therapeutics, said, “I am thrilled to welcome Dr. Langer as a Senior Advisor.  He brings a wealth of experience in supporting drug development companies from mid-stage clinical activity through commercial success, and he will be a valuable asset as we interact with large pharmaceutical companies and institutional investors.”

 

About Tryp Therapeutics

Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp's Psilocybin-For-Neuropsychiatric Disorders (PFN™) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of chronic pain and eating disorder indications. The company has announced upcoming Phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience.

For more information, please contact Tryp at:

1-833-811-8797
investors@tryptherapeutics.com
www.tryptherapeutics.com

 

Forward-Looking Information

Certain information in this news release constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp’s final prospectus available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

 

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Please sign up to receive updates